News
company
year
domain
Agios Pharmaceuticals 06.03.2017
Moderna 06.02.2017
T2 Biosystems 06.01.2017
Quanterix 05.17.2017
Axcella Therapeutics 05.11.2017
2017
Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma
N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density
Study Published in the Journal of Clinical Microbiology Highlights Detection of Lyme Disease-Causing Bacteria in Blood Using T2 Biosystems’ T2MR® Technology
Quanterix Launches the First Comprehensive Multiplex Panel to Study Traumatic Brain Injury Severity
Axcella Announces the Appointment of Ivana Magovcevic-Liebisch, Ph.D., J.D., as Executive Vice President, Chief Strategy and Corporate Development Officer